jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

TSH - Receptor Antibody (IgG)

Thyroid
image

Report in 96Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Checks thyroid function

₹4,900₹5,850

16% OFF

TSH - Receptor Antibody (IgG) Test Information Guide

  • Section 1: Why is it done?
    • Test Purpose: This test detects and measures immunoglobulin G (IgG) antibodies that bind to TSH (thyroid-stimulating hormone) receptors on thyroid cells. It identifies autoimmune thyroid disease, particularly Graves' disease.
    • Primary Indications: Diagnosis of Graves' disease (hyperthyroidism caused by autoimmune thyroiditis); Differential diagnosis of thyroid disorders; Evaluation of thyroid eye disease (Graves' ophthalmopathy); Assessment of thyroid autoimmunity in pregnant women; Monitoring disease activity and treatment response
    • Typical Timing and Circumstances: Ordered when patients present with symptoms of hyperthyroidism (tachycardia, tremor, weight loss, heat intolerance); When TSH is suppressed with elevated free T3/T4; During initial diagnosis of Graves' disease; In pregnant women with known or suspected Graves' disease to assess risk of neonatal thyroiditis; During remission to assess relapse risk; When eye symptoms suggestive of thyroid-associated ophthalmopathy are present
  • Section 2: Normal Range
    • Reference Range Values: Negative/Normal: < 0.3 IU/L or < 1.0 mIU/L (varies by laboratory); Borderline: 0.3-1.0 IU/L; Positive/Abnormal: > 1.0 IU/L
    • Units of Measurement: International Units per Liter (IU/L) or milli-International Units per Liter (mIU/L); Some laboratories report as qualitative results (Positive/Negative) or as a ratio value
    • Result Interpretation Guide: Negative Result: Indicates absence of TSH receptor antibodies; Rules out Graves' disease as primary diagnosis; Does not exclude other forms of hyperthyroidism or thyroiditis Positive Result: Confirms presence of TSH-receptor antibodies; Highly specific for Graves' disease; Can indicate active autoimmune thyroid disease Borderline Result: Warrants repeat testing; May indicate early disease or low-level antibody production; Clinical correlation with symptoms and other thyroid tests essential
    • Normal vs Abnormal Significance: Normal (Negative): No TSH-receptor autoimmunity detected; Compatible with euthyroid state or non-autoimmune thyroid disease Abnormal (Positive): Presence of autoimmune thyroid disorder; Indicates pathogenic antibodies likely causing or contributing to thyroid dysfunction; Requires clinical management and monitoring
  • Section 3: Interpretation
    • Detailed Result Interpretation: Strongly Positive (> 5 IU/L): Indicates active Graves' disease; High likelihood of thyroid-associated ophthalmopathy; May correlate with more severe hyperthyroidism; Suggests need for aggressive treatment Moderately Positive (1-5 IU/L): Consistent with Graves' disease; Supports diagnosis but intensity may vary; Can indicate remission or partial treatment response Weakly Positive (0.3-1.0 IU/L): May represent early disease or recovery phase; Borderline requires correlation with clinical presentation and other thyroid markers Negative (< 0.3 IU/L): Does not exclude hyperthyroidism; Rules out Graves' disease; Suggests thyroiditis, iodine-induced, or other causes
    • Clinical Significance of Results: Positive result provides definitive diagnosis of Graves' disease; High specificity (>90%) for autoimmune thyroid dysfunction; Can predict recurrence after cessation of antithyroid drugs; Presence correlates with risk of thyroid eye disease; Antibody levels may fluctuate with disease activity and treatment
    • Factors Affecting Readings: Disease activity and severity; Effectiveness of current treatment (antithyroid medications, beta-blockers, radioiodine, surgery); Time since diagnosis (early vs chronic disease); Immune system status; Pregnancy and postpartum period (hormonal influences); Infection or other triggers; Laboratory assay method and sensitivity; Individual immunological response variation
    • Result Patterns and Their Meaning: Persistently High Levels: Suggests ongoing autoimmune activation; May indicate need for different treatment approach; Higher risk of relapse if treatment stopped Declining Levels: Indicates treatment response; Suggests disease remission; May signal appropriate time to consider treatment adjustment Negative Converting to Positive: Suggests disease relapse or reactivation; Warrants clinical evaluation and possible treatment intensification Persistently Negative with Hyperthyroidism: Excludes Graves' disease; Consider other diagnoses (thyroiditis, toxic nodule, iodine-induced)
  • Section 4: Associated Organs
    • Primary Organ System Involved: Thyroid Gland (primary target organ); Orbits/Eyes (secondary immune target in Graves' ophthalmopathy); Skin (rarely affected in thyroid dermopathy); Anterior pituitary (indirectly affected through thyroid hormone feedback)
    • Associated Diseases and Conditions: Graves' Disease (primary autoimmune hyperthyroidism); Thyroid-Associated Ophthalmopathy (Graves' eye disease); Thyroid Dermopathy (pretibial myxedema); Graves' Acropachy (clubbing of fingers); Other Autoimmune Diseases (Type 1 diabetes, celiac disease, pernicious anemia); Secondary Hypothyroidism (after radioiodine or surgery); Thyroid Cancer (associated with chronic inflammation); Thyroid Nodules and Goiter
    • Diagnostic Capabilities: Confirms diagnosis of Graves' disease with high specificity; Differentiates Graves' from other causes of hyperthyroidism (thyroiditis, toxic nodule); Identifies patients at risk for thyroid eye disease; Assists in classification of autoimmune thyroid disorders; Helps stratify patient risk for disease relapse; Supports diagnosis in atypical presentations
    • Potential Complications of Abnormal Results: Thyroid Storm (life-threatening hypermetabolic crisis); Atrial Fibrillation (cardiac arrhythmia); Heart Failure (from prolonged hyperthyroidism); Osteoporosis (from chronic thyroid hormone excess); Thyroid Eye Disease (vision-threatening complications); Thyroid Infertility and Reproductive Issues; Psychiatric Manifestations (anxiety, mood disorders); Secondary Thyroid Cancer Risk; Complications from treatment (radioiodine, antithyroid drugs)
  • Section 5: Follow-up Tests
    • Initial Recommended Tests: Serum TSH Level (baseline thyroid function assessment); Free T4 (thyroxine) and Free T3 (triiodothyronine) levels; Total T3 and Total T4 (alternative measurement method); Thyroid Peroxidase Antibody (TPO-Ab); Thyroglobulin Antibody (TgAb); Complete Blood Count (assess for agranulocytosis if antithyroid drugs considered)
    • Additional Investigations Based on Results: Thyroid Ultrasound (assess gland size, heterogeneity, nodules); Thyroid Radioiodine Uptake Scan (confirm diagnosis, assess functionality); Ophthalmologic Examination (if eye symptoms present); Orbital MRI or CT (evaluate Graves' ophthalmopathy severity); Thyroid Function Panel Repeat Testing; Liver Function Tests (baseline for antithyroid drug therapy); EKG (assess for cardiac complications); Echocardiogram (if cardiac involvement suspected)
    • Monitoring Frequency for Ongoing Conditions: During Acute Phase: Thyroid function every 4-6 weeks until controlled; TSH-R antibodies may repeat at 3-6 months to assess response During Maintenance Treatment: Thyroid function every 2-3 months; TSH-R antibodies annually or when assessing remission potential Post-Treatment Remission: Thyroid function every 6-12 months; TSH-R antibodies every 6-12 months to assess relapse risk Pregnant Women with Graves' Disease: Thyroid function every 4-6 weeks; TSH-R antibodies monthly in third trimester (assess neonatal risk)
    • Complementary and Related Tests: TSH-Binding Inhibitory Immunoglobulin (TBII) - measures functional blocking antibodies; Thyroid-Stimulating Immunoglobulin (TSI) - functional assay for bioactive antibodies; Anti-TPO and Anti-Thyroglobulin - assess for concurrent autoimmune thyroiditis; Dynamic TSH Receptor Occupancy Tests - emerging functional assays; Genotyping for HLA Association; Screening for Other Autoimmune Conditions (tissue transglutaminase for celiac disease, islet cell antibodies for diabetes)
  • Section 6: Fasting Required?
    • Fasting Requirement: NO - Fasting is NOT required for TSH-Receptor Antibody (IgG) testing. This test can be performed on a blood sample obtained at any time of day, regardless of meal intake.
    • Specimen Collection Requirements: Standard venipuncture (blood draw) into appropriate serum separator tube (SST) or gold top tube; Approximately 5-7 mL of blood needed; No special handling required; Room temperature storage acceptable before transport
    • Medications to Continue: Continue all current thyroid medications (PTU, Methimazole, Levothyroxine); Continue beta-blockers if prescribed; Continue all other chronic medications as prescribed; TSH-R antibody levels are not affected by current medications and reflect true disease state
    • Medications to Avoid: No medications need to be avoided specifically for this test; However, discontinue biotin supplements at least 72 hours before testing (can interfere with some immunoassay methods); High-dose corticosteroids may be noted but should not be discontinued
    • Other Patient Preparation: No special fasting; Can eat and drink normally before test; No fluid restrictions required; Patient should be calm and relaxed before blood draw to minimize stress response; Inform healthcare provider of recent infections or illnesses; Advise provider of recent vaccinations; Report any recent iodine contrast exposure (can affect thyroid function); No rest or exercise restrictions before test; Timing: Morning collection preferred for consistency with other thyroid tests, though not required; Ensure proper hydration for easier blood draw

How our test process works!

customers
customers